Farnext, an advanced clinical-stage biopharmaceutical company developing new therapies for neurodegenerative diseases without a satisfactory therapeutic solution, today announced the completion of a reverse stock split, as decided by its Board of Directors on September 26, 2022, for one new share with one share. New. par value of 1 euro in exchange for 5,000 old shares with a par value of 0.0002 euro, as authorized by the general meeting on June 17, 2022 under the provisions of its eighth resolution.
This merger allows the company to reduce the volatility of Farnext’s share price and enhance its stability.